Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Cytarabine in CML Chronic Phase
NCT00022490Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2001
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Rate of Major Cytogenetic Response at 6 months. Started Jun 2001; status: terminated.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00022490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022490.